SOURCE: Streetwise Reports

Streetwise Reports

March 17, 2016 09:00 ET

Laidlaw & Co. Analyst Jim Molloy Interviewed by The Life Sciences Report

SAN FRANCISCO, CA--(Marketwired - March 17, 2016) - After a devastating start to 2016, biotech stocks have snapped back. Laidlaw & Co. analyst Jim Molloy likes the resurgence he's seeing in biotechnology share prices, but cautions that confirmation of a recovery will require cash-laden drug developers to begin acquiring smaller biotechs trading at depressed market valuations. In the meantime, Molloy says, individual and small institutional investors can still buy growth stories at bargain prices. In this interview with The Life Sciences Report, Molloy mentions three names with near-term catalysts that, with good data, can bring a needed lift to biotech portfolios.

Included in this interview are: DURECT Corp. (NASDAQ: DRRX) and Cerecor Inc. (NASDAQ: CERC).

The Life Sciences Report:  A lot of factors worked against biotech last year, and especially in the first month of 2016. A couple of drug pricing issues became very public even in nonfinancial media, and that news became a showcase for politicians. We had a Federal Reserve tightening, and the threat of more tightening. To top it off, we saw an implosion of the Chinese capital markets in January, and that was contagious. Do you feel the smoke has cleared for biotech by now?

Jim Molloy: It's hard when you're in the middle of the smoke to see whether it is clearing. But it seems that more sentiment on the Street leans toward the belief that the worst may be behind us, and that we may be reaching the bottom. One of the things I think would demonstrate the turnaround is...

Continue reading this interview: From Acorns Mighty Biotech Trees Can Grow: Laidlaw's Jim Molloy

About Streetwise Reports - The Life Sciences Report

Investors rely on The Life Sciences Report to share investment ideas for the biotech, pharmaceutical, medical device, and diagnostics industries. Our exclusive interviews with leading industry experts and analysts provide a clear picture of the causes of macro-economic shifts and the strategies that help you capitalize on developing trends.


DURECT Corp. is a sponsor of Streetwise Reports. Cerecor Inc. paid to distribute. James Molloy had final approval of the content and is wholly responsible for the validity of the statements. Opinions expressed are the opinions of Mr. Molloy and not of The Life Sciences Report or its officers. The interview does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility.

Please see Streetwise Reports' terms of use and full legal disclaimer.

Contact Information